Measurement of Intestinal Permeability in Intensive Care Patients With Single or Multiple Organ Failure

Recruiting Observational Study
Multivisceral Failure Syndrome Monovisceral Failure Infection in ICU
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
126 (estimated)
Sponsor
Direction Centrale du Service de Santé des Armées · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Multivisceral failure syndrome (MVFS) in humans is associated with a very high risk of mortality, ranging between 30 and 50%. This syndrome is associated with significant systemic inflammation and a high risk of bacteremia, the origin of which is not always identified. Among the possible causes of bacteremia, digestive translocation is the most probable but has not been formally proven to date. Th…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Patient with single organ failure, secondary to sepsis, hospitalized in intensive care for a foreseeable duration of \> 48 hours * SAPS2 between 20 and 40 at the sixth hour after the diagnosis of organ failure. * Consent from the patient or their trusted person. * Affiliation t…
Contacts

Michael RERA, PhD

+33781945974

michael.rera@cnrs.fr

CONTACT

Rachel HAUS, PhD

evdg-dpar.contact.fct@intradef.gouv.fr

CONTACT